Utama › Sistem Imun dan Gangguan › North Carolina
Kajian klinikal Sistem Imun dan Gangguan di North Carolina
7 kajian untuk Sistem Imun dan Gangguan sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Duke Cancer Center Cary, Cary
- Duke University Medical Center, Durham
- East Carolina University, Greenville
- dan 5 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04242095A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06948318Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05826535A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 20, Charlotte
Mengambil pesertaFasa 2
Umur 18 hingga 74 · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT07037901CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Apr 2026 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Levine Cancer Institute, Charlotte
- Duke University Hospital, Durham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Dis 2025 · NCT06619561Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.